Robert G Fassett

Summary

Affiliation: University of Queensland
Country: Australia

Publications

  1. ncbi Astaxanthin in cardiovascular health and disease
    Robert G Fassett
    School of Medicine, The University of Queensland, Brisbane, Queensland 4000, Australia
    Molecules 17:2030-48. 2012
  2. ncbi Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial
    Robert G Fassett
    Renal Medicine Department, Royal Brisbane and Women s Hospital, Brisbane, Australia
    Nephrol Dial Transplant 27:182-9. 2012
  3. ncbi Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial
    Robert G Fassett
    Renal Medicine, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Atherosclerosis 213:218-24. 2010
  4. ncbi Palliative care in end-stage kidney disease
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, School of Medicine, The University of Queensland, Brisbane, St Lucia, Queensland, Australia
    Nephrology (Carlton) 16:4-12. 2011
  5. ncbi Cardiovascular disease in peritoneal dialysis patients
    R G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Panminerva Med 51:151-61. 2009
  6. ncbi Astaxanthin, oxidative stress, inflammation and cardiovascular disease
    Robert G Fassett
    School of Human Movement Studies and School of Medicine, The University of Queensland, Queensland, Australia
    Future Cardiol 5:333-42. 2009
  7. ncbi Astaxanthin: a potential therapeutic agent in cardiovascular disease
    Robert G Fassett
    Renal Research Royal Brisbane and Women s Hospital and The University of Queensland School of Medicine, Butterfield Street, Brisbane, Queensland 4029, Australia
    Mar Drugs 9:447-65. 2011
  8. ncbi Biomarkers in chronic kidney disease: a review
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Kidney Int 80:806-21. 2011
  9. ncbi Omega-3 polyunsaturated fatty acids in the treatment of kidney disease
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Am J Kidney Dis 56:728-42. 2010
  10. ncbi Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Herston, Brisbane, Queensland, Australia
    BMC Nephrol 9:17. 2008

Collaborators

Detail Information

Publications27

  1. ncbi Astaxanthin in cardiovascular health and disease
    Robert G Fassett
    School of Medicine, The University of Queensland, Brisbane, Queensland 4000, Australia
    Molecules 17:2030-48. 2012
    ..On the basis of the promising results of experimental cardiovascular studies and the physicochemical and antioxidant properties and safety profile of astaxanthin, clinical trials should be undertaken...
  2. ncbi Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial
    Robert G Fassett
    Renal Medicine Department, Royal Brisbane and Women s Hospital, Brisbane, Australia
    Nephrol Dial Transplant 27:182-9. 2012
    ....
  3. ncbi Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial
    Robert G Fassett
    Renal Medicine, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Atherosclerosis 213:218-24. 2010
    ..The effect of atorvastatin on kidney function was assessed in patients with stages 2-4 chronic kidney disease...
  4. ncbi Palliative care in end-stage kidney disease
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, School of Medicine, The University of Queensland, Brisbane, St Lucia, Queensland, Australia
    Nephrology (Carlton) 16:4-12. 2011
    ..The objective of this review is to summarize published studies and evidence-based guidelines, core curricula, position statements, standards and tools in palliative care in end-stage kidney disease...
  5. ncbi Cardiovascular disease in peritoneal dialysis patients
    R G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Panminerva Med 51:151-61. 2009
    ..Other registry data do not support this. Further long-term studies assessing surrogate and hard endpoint cardiovascular outcomes in peritoneal dialysis are required...
  6. ncbi Astaxanthin, oxidative stress, inflammation and cardiovascular disease
    Robert G Fassett
    School of Human Movement Studies and School of Medicine, The University of Queensland, Queensland, Australia
    Future Cardiol 5:333-42. 2009
    ..These may lead to large intervention trials assessing cardiovascular morbidity and mortality...
  7. ncbi Astaxanthin: a potential therapeutic agent in cardiovascular disease
    Robert G Fassett
    Renal Research Royal Brisbane and Women s Hospital and The University of Queensland School of Medicine, Butterfield Street, Brisbane, Queensland 4029, Australia
    Mar Drugs 9:447-65. 2011
    ..Cardiovascular clinical trials are warranted based on the physicochemical and antioxidant properties, the safety profile and preliminary experimental cardiovascular studies of astaxanthin...
  8. ncbi Biomarkers in chronic kidney disease: a review
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Kidney Int 80:806-21. 2011
    ..Although none are ready for use in clinical practice, it is timely to review the role of such biomarkers in predicting CKD progression and/or CVD risk in CKD...
  9. ncbi Omega-3 polyunsaturated fatty acids in the treatment of kidney disease
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Am J Kidney Dis 56:728-42. 2010
    ..Well-designed, adequately powered, randomized, controlled clinical trials are required to further investigate the potential benefits of omega-3 polyunsaturated fatty acids on the progression of kidney disease and patient survival...
  10. ncbi Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Herston, Brisbane, Queensland, Australia
    BMC Nephrol 9:17. 2008
    ..The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness, oxidative stress and inflammation in renal transplant patients...
  11. ncbi Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial
    Robert G Fassett
    Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    J Atheroscler Thromb 17:235-41. 2010
    ..Hence, the aim of this study was to assess the long-term effects of atorvastatin on arterial stiffness and central blood pressure in patients with CKD...
  12. ncbi Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients--an observational study
    Robert G Fassett
    Renal Research, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    BMC Nephrol 10:8. 2009
    ....
  13. ncbi Assessment of arterial stiffness, oxidative stress and inflammation in acute kidney injury
    Robert G Fassett
    Renal Medicine, Royal Brisbane and Women s Hospital, Queensland, Australia
    BMC Nephrol 10:15. 2009
    ..The aim of this study is to elucidate the vascular changes in acute kidney injury. We hypothesise that arterial stiffness will be increased during acute kidney injury and this will return to normal after kidney function recovers...
  14. ncbi Randomised controlled trial to determine the appropriate time to initiate peritoneal dialysis after insertion of catheter to minimise complications (Timely PD study)
    Dwarakanathan Ranganathan
    Renal Medicine, Royal Brisbane and Women s Hospital, Brisbane, Queensland, 4029, Australia
    BMC Nephrol 11:11. 2010
    ..Previous studies are observational and mostly compare immediate with delayed use. The primary objective is to determine the safest and shortest time interval between surgical placement of a Tenckhoff catheter and starting PD...
  15. ncbi The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats
    Jonathan M Peake
    The University of Queensland, School of Human Movement Studies, Brisbane, Australia
    Mol Nutr Food Res 55:400-10. 2011
    ..We examined whether dietary supplementation with fish oil modulates inflammation, fibrosis and oxidative stress following obstructive renal injury...
  16. ncbi Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients
    Melanie L Blackhall
    School of Human Movement Studies, The University of Queensland, Queensland, Australia
    Nephrol Dial Transplant 20:1970-5. 2005
    ..CONCLUSION: In CsA-treated RTRs, antioxidant supplementation decreased blood CsA, which may affect adequacy of immunosuppression...
  17. ncbi Antioxidant therapy in hemodialysis patients: a systematic review
    Jeff S Coombes
    School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia
    Kidney Int 81:233-46. 2012
    ..Two intervention trials using different antioxidants have found CVD benefits, suggesting that this line of therapy is effective in this resistant population. These studies require validation in larger, adequately powered trials...
  18. ncbi Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients
    Ashleigh Reed
    School of Human Movement Studies, The University of Queensland, St Lucia, Queensland, 4072, Australia
    BMC Nephrol 10:32. 2009
    ..Therefore the aim of this study is to investigate the effect of different doses of oral alpha tocopherol on oxidative stress in haemodialysis patients with elevated oxidative stress and the time taken to achieve this effect...
  19. ncbi Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting
    Robert G Fassett
    School of Human Movement Studies, University of Queensland, Brisbane, Australia
    J Ren Nutr 17:235-42. 2007
    ..The study objective was to determine the dietary intake of patients with chronic kidney disease before and after filtering for suspected underreporters and to investigate the impact of underreporting on the interpretation of diet data...
  20. ncbi Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease
    Robert G Fassett
    Renal Medicine, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Scand J Urol Nephrol 44:56-61. 2010
    ..Experimental and clinical studies have suggested that statins may slow the progression of chronic kidney disease in general and ADPKD specifically...
  21. ncbi Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study
    Dwarakanathan Ranganathan
    Renal Medicine, Royal Brisbane and Women s Hospital, Brisbane, Queensland, 4029 Australia
    BMC Nephrol 10:42. 2009
    ..The aim of this study is to examine a model of gentamicin pharmacokinetics and to develop an intraperitoneal drug dosing regime that maximises bacterial killing and minimises toxicity...
  22. ncbi Oxidative stress biomarkers as predictors of cardiovascular disease
    Natalie A Strobel
    Exercise and Oxidative Stress Research Group, School of Human Movement Studies, The University of Queensland, St Lucia, Queensland 4072, Australia
    Int J Cardiol 147:191-201. 2011
    ..Furthermore, it is important to note that the methods used to assess oxidative stress in these studies are indirect, and the evidence that the various methods actually reflect oxidative stress in vivo is limited...
  23. ncbi Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection
    Andrew C Bulmer
    School of Human Movement Studies, University of Queensland, St Lucia, Queensland 4067, Australia
    Atherosclerosis 199:390-6. 2008
    ..96+/-0.31; control: 0.73+/-0.21; P=0.072). In summary, individuals with GS have an increased circulating antioxidant status and an improved resistance to serum oxidation which may partially explain their reduced prevalence of CVD...
  24. ncbi The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats
    Cecilia M Shing
    School of Human Life Sciences, University of Tasmania, Launceston, Australia
    Transpl Int 25:337-46. 2012
    ..At the doses administered in this model, the immunosuppressants exerted varying effects on vascular function...
  25. ncbi Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
    David Wayne Johnson
    Australian Kidney Trials Network, School of Population Health, University of Queensland, Brisbane, Australia
    BMC Nephrol 9:8. 2008
    ..The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients...
  26. ncbi Physiological and performance effects of glycerol hyperhydration and rehydration
    Simon P van Rosendal
    The University of Queensland, School of Human Movement Studies, Brisbane, Queensland, Australia
    Nutr Rev 67:690-705. 2009
    ..In summary, while glycerol and fluid ingestion results in hyperhydration, the documented benefits to exercise performance remain inconsistent...
  27. ncbi Laparoscopic adjustable gastric band in an obese unrelated living donor prior to kidney transplantation: a case report
    Anoop N Koshy
    School of Human Movement Studies, The University of Queensland, St, Lucia, Queensland, Australia
    J Med Case Reports 4:107. 2010
    ..Many centres exclude obese donors from living donor transplant programs. Diet, exercise and medication are often ineffective weight loss interventions for donors, hence bariatric surgery should be considered...